HSBC downgrades Eli Lilly, says shares are ‘priced to perfection’ By Investing.com

HSBC downgraded Eli Lilly to Reduce and cut its price target to $850 from $1,070 (≈-21%), citing overly optimistic expectations for the obesity-drug market. HSBC pegs obesity TAM at $80–$120bn by 2032 versus consensus >$150bn, warns of intensifying price competition and planned 2026 price cuts, and flags risks around oral drug uptake/compliance and an assumed $1.5bn 2026 inventory build. The bank also notes Lilly’s heavier reliance on cash-pay channels versus Novo Nordisk may expose it to economic-cycle and AI-linked labour-market risks, while still viewing the broader Healthcare sector as likely to outperform but with elevated multiple risks.

Analysis

The market has likely over-allocated to a binary obesity-growth narrative; that concentration creates asymmetric downside for the largest exposed names if adoption or pricing proves weaker than modeled. A 20–40% haircut to long-term TAM assumptions compresses terminal revenue for high-multiple incumbents by a similar order, which cascades through valuation models because much of current equity upside is carried in out-year cash flows.

Second-order winners include scale players with more diversified franchise and payer mix: firms that capture a broader share of insurance-reimbursed channels, or that own complementary diabetes/metabolic portfolios, will withstand downward price pressure better than niche cash-pay-heavy launches. Conversely, contract manufacturers, specialty pharmacies and distribution partners face inventory destocking and order smoothing risks — expect near-term top-line volatility even if underlying demand recovers cyclically.

Key catalysts and timelines: near-term (0–6 months) look for real-world persistence/adherence data, inventory disclosures and any guidance revisions that force re-rates; medium-term (6–24 months) look for payer policy updates, negotiated price actions and competitive oral launch performance. A true reversal would require convincing persistence and payer economics demonstrating net-cost offsets within 1–2 years or materially differentiated clinical benefit that restores pricing power; absent that, multiple decompression is the path of least resistance.

Key Decisions for Investors

• Short LLY equity (or buy 9–12 month put spread) sized 1–2% of fund NAV: target 25–35% downside if consensus revenue falls 20–30% over 12 months; hedge tail risk with a small long-dated call (~<0.25% NAV). Cut if quarterly sales beat consensus by >10% or if persistence metrics in RWD exceed expectations.
• Pair trade — short LLY / long NVO, equal notional, 12-month horizon: we expect 15–25% relative outperformance for the long leg driven by scale, payer leverage and channel diversification. Size at 1–2% net directional exposure; unwind if spread narrows <5% within 3 months or if both post materially positive pricing guidance.
• Long consumer discretionary re-allocation: initiate long DAL and ULCC (combined 1–1.5% NAV) via 6–9 month call spreads to capture potential rotation of discretionary spend if cash-pay healthcare sensitivity reduces. Take profits on a 20–30% move; stop-loss a 12–15% adverse move.
• Event hedge: buy short-dated puts on specialty pharmacy/CMO suppliers (small tactical allocation) to protect against inventory destocking risk over next 3–6 months — these can pay off asymmetric declines if order flow normalizes downwards rapidly.